Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Viral Structure00:56

Viral Structure

Viruses are extraordinarily diverse in shape and size, but they all have several structural features in common. All viruses have a core that contains a DNA- or RNA-based genome. The core is surrounded by a protective coat of proteins called the capsid. The capsid is composed of subunits called capsomeres. The capsid and genome-containing core are together known as the nucleocapsid.
Vaccine Production01:23

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
Vaccines01:21

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...
Introduction to Virus01:28

Introduction to Virus

Viruses are unique biological entities that blur the boundary between living and non-living systems. Although they lack cellular structure and metabolic processes, they can exhibit characteristics of life when infecting a host. Their defining feature is a nucleic acid core, composed of either DNA or RNA, encapsulated within a protein coat called a capsid. This simple structure allows them to invade host cells and use their machinery for replication efficiently.Viral Structure and...
Inhibitors of Virion Maturation and Assembly01:19

Inhibitors of Virion Maturation and Assembly

As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...
Immune Response Against Viral Pathogens01:29

Immune Response Against Viral Pathogens

The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A VLP-based immunogen that elicits selective anti-Myostatin antibodies, enhances muscle mass and strength, and reduces adiposity.

bioRxiv : the preprint server for biology·2026
Same author

A Comparative Evaluation of Adjuvants for Enhancing Antibody Responses to a Nanoparticle-Based Malaria Vaccine.

bioRxiv : the preprint server for biology·2026
Same author

Immunization with VLP-based vaccines induces high IgG antibody titers in dermal interstitial fluid.

NPJ vaccines·2025
Same author

Formulation, Characterization, and In Vivo Immunogenicity of Heat-Stabilized Dissolvable Microneedles Containing a Novel VLP Vaccine.

Pharmaceutical research·2025
Same author

Multi-phase Training in Virus-Like Particle Synthesis to Foster Science Self-efficacy in Students With Minimal Laboratory Experience.

Bio-protocol·2025
Same author

Virus-like particle vaccines targeting a key epitope in circumsporozoite protein provide sterilizing immunity against malaria.

NPJ vaccines·2025

Related Experiment Video

Updated: Jul 14, 2026

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle (VLP)-Based Vaccines Using a Capture Assay
05:15

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle (VLP)-Based Vaccines Using a Capture Assay

Published on: February 10, 2022

Virus-like particles: flexible platforms for vaccine development.

Bryce Chackerian1

  • 1University of New Mexico, Department of Molecular Genetics and Microbiology, Center for Infectious Disease and Immunity, Cancer Research and Treatment Center, Cancer Biology Program, School of Medicine, Albuquerque, NM 87131, USA. bchackerian@salud.unm.edu

Expert Review of Vaccines
|June 5, 2007
PubMed
Summary

Virus-like particles (VLPs) are self-assembling protein structures that mimic viruses. They show great promise as versatile vaccine platforms for infectious diseases and chronic conditions.

More Related Videos

Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
08:07

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

Published on: July 25, 2022

Related Experiment Videos

Last Updated: Jul 14, 2026

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle (VLP)-Based Vaccines Using a Capture Assay
05:15

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle (VLP)-Based Vaccines Using a Capture Assay

Published on: February 10, 2022

Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
08:07

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

Published on: July 25, 2022

Area of Science:

  • Biotechnology
  • Immunology
  • Vaccinology

Background:

  • Virus-like particles (VLPs) are non-infectious, self-assembled structures composed of viral structural proteins.
  • VLPs are antigenically identical to native viruses or subviral particles, eliciting a strong immune response.
  • Their repetitive, dense array structure offers significant advantages for vaccine development.

Purpose of the Study:

  • To review the advancement of VLP-based platform technologies for vaccine creation.
  • To explore VLP applications against various pathogens.
  • To discuss the potential of VLPs for targeting non-traditional antigens in chronic diseases.

Main Methods:

  • Review of existing literature on VLP technology.
  • Analysis of VLP self-assembly mechanisms.
  • Evaluation of VLP immunogenicity and efficacy studies.

Main Results:

  • VLP technology has matured into a robust platform for vaccine development.
  • VLPs are effective against a range of viral pathogens.
  • Emerging applications include therapeutic vaccines for chronic diseases targeting self-antigens.

Conclusions:

  • Virus-like particles represent a highly adaptable and effective platform for vaccine design.
  • VLP technology holds significant potential for both prophylactic and therapeutic applications.
  • Further research into VLP applications for chronic diseases is warranted.